Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge

Vaccine

Volumn 29, Issue 4, 2011, Pages 784-794

  Moustafa, Dina ^a   Garg, Virendra K ^a   Jain, Neeta ^b   Sriranganathan, Nammalwar ^b   Vemulapalli, Ramesh ^a  

^a PURDUE UNIVERSITY   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

B. neotomae; Broad protection; Brucellosis; Gamma radiation; Vaccine

Indexed keywords

BRUCELLA VACCINE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BRUCELLA; BRUCELLA ABORTUS; BRUCELLA MELITENSIS; BRUCELLA NEOTOMAE; BRUCELLA SUIS; BRUCELLOSIS; CONTROLLED STUDY; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; GAMMA IRRADIATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BACTERIAL; BRUCELLA; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; FEMALE; GAMMA RAYS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 78650571634     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.018     Document Type: Article

References (53)

1. Corbel M.J. Brucellosis: an overview. Emerg Infect Dis 1997, 3(2):213-221.
2. Franco M.P., Mulder M., Gilman R.H., Smits H.L. Human brucellosis. Lancet Infect Dis 2007, 7(12):775-786.
3. Cutler S.J., Whatmore A.M., Commander N.J. Brucellosis-new aspects of an old disease. J Appl Microbiol 2005, 98(6):1270-1281.
4. Pappas G., Papadimitriou P., Akritidis N., Christou L., Tsianos E.V. The new global map of human brucellosis. Lancet Infect Dis 2006, 6(2):91-99.
5. Ficht T.A., Kahl-McDonagh M.M., Arenas-Gamboa A.M., Rice-Ficht A.C. Brucellosis: the case for live, attenuated vaccines. Vaccine 2009, 27:D40-D43.
6. Schurig G.G., Sriranganathan N., Corbel M.J. Brucellosis vaccines: past, present and future. Vet Microbiol 2002, 90(1-4):479-496.
7. Perkins S.D., Smither S.J., Atkins H.S. Towards a Brucella vaccine for humans. FEMS Microbiol Rev 2010, 34(3):379-394.
8. Blasco J.M., Díaz R. Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 1993, 342(8874):805.
9. Stoenner H.G., Lackman D.B. A new species of Brucella isolated from the desert wood rat, Neotoma lepida Thomas. Am J Vet Res 1957, 18(69):947-951.
10. Kovach M.E., Elzer P.H., Hill D.S., Robertson G.T., Farris M.A., Roop R.M., et al. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 1995, 166(1):175-176.
11. Vemulapalli R., He Y., Boyle S.M., Sriranganathan N., Schurig G.G. Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses. Infect Immun 2000, 68(6):3290-3296.
12. McQuiston J.R., Schurig G.G., Sriranganathan N., Boyle S.M. Transformation of Brucella species with suicide and broad host-range plasmids. Methods Mol Biol 1995, 47:143-148.
13. Sanakkayala N., Sokolovska A., Gulani J., HogenEsch H., Sriranganathan N., Boyle S.M., et al. Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51. Clin Diagn Lab Immunol 2005, 12(12):1429-1436.
14. Bounaadja L., Albert D., Chenais B., Henault S., Zygmunt M.S., Poliak S., et al. Real-time PCR for identification of Brucella spp.: a comparative study of IS711, bcsp31 and per target genes. Vet Microbiol 2009, 137(1/2):156-164.
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
16. Morrison D.C., Leive L. Fractions of Lipopolysaccharide from Escherichia coli O111-B4 prepared by two extraction procedures. J Biol Chem 1975, 250(8):2911-2919.
17. Phillips M., Pugh G.W., Deyoe B.L. Chemical and protective properties of Brucella lipopolysaccharide obtained by butanol extraction. Am J Vet Res 1989, 50(3):311-317.
18. Vemulapalli R., He Y., Cravero S., Sriranganathan N., Boyle S.M., Schurig G.G. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun 2000, 68(6):3286-3289.
19. Vemulapalli R., Duncan A.J., Boyle S.M., Sriranganathan N., Toth T.E., Schurig G.G. Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B abortus RB51. Infect Immun 1998, 66(12):5684-5691.
20. Onate A.A., Vemulapalli R., Andrews E., Schurig G.G., Boyle S., Folch H. Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun 1999, 67(2):986-988.
21. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J.D., Zajac A.J., Miller J., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8(2):177-187.
22. Schurig G.G., Roop R.M., Bagchi T., Boyle S., Buhrman D., Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol 1999, 28(2):171-188.
23. Bricker B.J., Tabatabai L.B., Judge B.A., Deyoe B.L., Mayfield J.E. Cloning expression, and occurrence of the Brucella Cu-Zn superoxide dismutase. Infect Immun 1990, 58(9):2935-2939.
24. Stoenner H.G. The behavior of Brucella neotomae and Brucella suis in reciprocal superinfection experiments in mice and guinea pigs. Am J Vet Res 1963, 24:376-380.
25. Hubbert W.T., Miller J.N. Studies on immunity in experimental leptospirosis: the immunogenicity of Leptospira icterohemorrhagiae attenuated by gamma-irradiation. J Immunol 1965, 95(4):759-764.
26. Jarrett W.F., Jennings F.W., Mc I.W., Mulligan W., Urquhart G.M. Irradiated helminth larvae in vaccination. Proc R Soc Med 1958, 51(9):743-744.
27. Martin S.S., Bakken R.R., Lind C.M., Garcia P., Jenkins E., Glass P.J., et al. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine 2010, 28(4):1031-1040.
28. Datta S.K., Okamoto S., Hayashi T., Shin S.S., Mihajlov I., Fermin A., et al. Vaccination with irradiated Listeria induces protective T cell immunity. Immunity 2006, 25(1):143-152.
29. Magnani D.M., Harms J.S., Durward M.A., Splitter G.A. Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice. Infect Immun 2009, 77(11):5181-5189.
30. Dhar N., Rao V., Tyagi A.K. Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of M. tuberculosis. FEMS Microbiol Lett 2000, 190(2):309-316.
31. Rao V., Dhar N., Tyagi A.K. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guérin. Scand J Immunol 2003, 58(4):449-461.
32. Yang X., Hudson M., Walters N., Bargatze R.F., Pascual D.W. Selection of protective epitopes of Brucella melitensis by DNA vaccination. Infect Immun 2005, 73(11):7297-7303.
33. Velikovsky C.A., Goldbaum F.A., Cassataro J., Estein S., Bowden R.A., Bruno L., et al. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect Immun 2003, 71(10):5750-5755.
34. Delpino M.V., Estein S.M., Fossati C.A., Baldi P.C., Cassataro Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 2007, 25(37/38):6721-6729.
35. Ria F., Penna G., Adorini L. Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur J Immunol 1998, 28(6):2003-2016.
36. Sharif M.N., Tassiulas I., Hu Y., Mecklenbrauker I., Tarakhovsky A., Ivashkiv L.B. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 2004, 172(10):6476-6481.
37. Fernandes D.M., Baldwin C.L. Interleukin-10 downregulates protective immunity to Brucella abortus. Infect Immun 1995, 63(3):1130-1133.
38. Cassataro J., Velikovsky C.A., Bruno L., Estein S.M., de la Barrera S., Bowden R., et al. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol 2007, 14(7):869-874.
39. Kahl-McDonagh M.M., Ficht T.A. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect Immun 2006, 74(7):4048-4057.
40. Gonzalez D., Grillo M.J., De Miguel M.J., Ali T., Arce-Gorvel V., Delrue R.M., et al. Brucellosis vaccines: assessment of Brucella melitensis lipopolysacharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One 2008, 3(7):e2760.
41. Yingst S., Hoover D.L. T cell immunity to brucellosis. Crit Rev Microbiol 2003, 29(4):313-331.
42. Limet J., Plommet A.M., Dubray G., Plommet M. Immunity conferred upon mice by anti-LPS monoclonal antibodies in murine brucellosis. Ann Inst Pasteur Immunol 1987, 138(3):417-424.
43. Araya L.N., Elzer P.H., Rowe G.E., Enright F.M., Winter A.J. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 1989, 143(10):3330-3337.
44. Montaraz J.A., Winter A.J., Hunter D.M., Sowa B.A., Wu A.M., Adams L.G. Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies. Infect Immun 1986, 51(3):961-963.
45. Elzer P.H., Jacobson R.H., Jones S.M., Nielsen K.H., Douglas J.T., Winter A.J. Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology 1994, 82(4):651-658.
46. Elzer P.H., Jacobson R.H., Nielsen K.H., Douglas J.T., Winter A.J. BALB/c mice infected with Brucella abortus express protracted polyclonal responses of both IgG2a and IgG3 isotypes. Immunol Lett 1994, 42(3):145-150.
47. Cloeckaert A., Jacques I., de Wergifosse P., Dubray G., Limet J.N. Protection against Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharides. Infect Immun 1992, 60(1):312-315.
48. Fernandez-Prada C.M., Nikolich M., Vemulapalli R., Sriranganathan N., Boyle S.M., Schurig G.G., et al. Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. Infect Immun 2001, 69(7):4407-4416.
49. Fernandez-Prada C.M., Zelazowska E.B., Nikolich M., Hadfield T.L., Roop R.M., Robertson G.L., et al. Interaction between Brucella melitensis and human phagocytes: bacterial surface O-polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis. Infect Immun 2003, 71(4):2110-2119.
50. Cloeckaert A., Weynants V., Godfroid J., Verger J.M., Grayon M., Zygmunt M.S. O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry. Clin Diagn Lab Immunol 1998, 5(6):862-870.
51. Caroff M., Bundle D.R., Perry M.B., Cherwonogrodzky J.W., Duncan J.R. Antigenic S-type lipopolysaccharide of Brucella abortus 1119-3. Infect Immun 1984, 46(2):384-388.
52. Bundle D.R., Cherwonogrodzky J.W., Perry M.B. Structural elucidation of the Brucella melitensis M antigen by high-resolution NMR at 500MHz. Biochemistry 1987, 26(26):8717-8726.
53. Arenas-Gamboa A.M., Ficht T.A., Kahl-McDonagh M.M., Rice-Ficht A.C. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun 2008, 76(6):2448-2455.